Get the Stockscreener App
12.35
3.79%
-0.4628
Novocure Ltd stock is traded at $12.35, with a volume of 1.11M.
It is down -3.79% in the last 24 hours and down -15.93% over the past month.
NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.
See More
Previous Close:
$12.81
Open:
$12.8
24h Volume:
1.11M
Relative Volume:
0.71
Market Cap:
$1.38B
Revenue:
$577.74M
Net Income/Loss:
$-149.78M
P/E Ratio:
-8.8194
EPS:
-1.4
Net Cash Flow:
$-78.21M
1W Performance:
-9.24%
1M Performance:
-15.93%
6M Performance:
-32.09%
1Y Performance:
-23.83%
1-Day Range:
$12.19
$12.80
1-Week Range:
$12.19
$14.22
52-Week Range:
$10.87
$34.13
Novocure Ltd Stock (NVCR) Company Profile
Name
Novocure Ltd
Sector
Industry
Phone
44 (0)15 3475 6700
Address
NO. 4 THE FORUM, ST. HELIER
Compare NVCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
12.33 | 1.43B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
123.81 | 214.96B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
98.94 | 149.24B | 19.35B | 2.78B | 3.49B | 1.8696 |
|
SYK
Stryker Corp
|
359.50 | 136.23B | 24.38B | 2.94B | 4.02B | 7.6145 |
|
MDT
Medtronic Plc
|
89.81 | 116.33B | 34.20B | 4.69B | 5.30B | 3.6218 |
|
EW
Edwards Lifesciences Corp
|
83.14 | 48.41B | 5.88B | 1.34B | 577.90M | 2.3455 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-25-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jul-08-25 | Initiated | Ladenburg Thalmann | Buy |
| Dec-02-24 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-16-24 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-20-23 | Resumed | JP Morgan | Neutral |
| Aug-28-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Aug-08-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-04-23 | Initiated | SVB Securities | Outperform |
| Jul-31-23 | Upgrade | Evercore ISI | Underperform → In-line |
| Jun-07-23 | Upgrade | Wedbush | Underperform → Neutral |
| May-16-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-17-23 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-06-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-05-23 | Reiterated | H.C. Wainwright | Buy |
| Nov-29-22 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-24-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-05-22 | Downgrade | Evercore ISI | In-line → Underperform |
| May-16-22 | Initiated | H.C. Wainwright | Buy |
| Feb-08-22 | Initiated | Loop Capital | Buy |
| Feb-02-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jan-20-22 | Upgrade | Truist | Hold → Buy |
| Jan-03-22 | Upgrade | Evercore ISI | Underperform → In-line |
| Jul-01-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-14-21 | Downgrade | Wedbush | Neutral → Underperform |
| Jan-25-21 | Reiterated | Piper Sandler | Overweight |
| Sep-23-20 | Initiated | Northland Capital | Outperform |
| Sep-18-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-17-20 | Downgrade | Truist | Buy → Hold |
| Jun-01-20 | Resumed | Oppenheimer | Perform |
| May-01-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Apr-09-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Mar-05-20 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Jul-29-19 | Upgrade | SunTrust | Hold → Buy |
| Jul-26-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-26-19 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-20-19 | Initiated | SunTrust | Hold |
| Nov-02-18 | Downgrade | Wells Fargo | Outperform → Market Perform |
| Jul-16-18 | Initiated | Evercore ISI | Outperform |
| Apr-18-18 | Reiterated | Mizuho | Buy |
| Feb-23-18 | Reiterated | Mizuho | Buy |
| May-24-17 | Upgrade | Wells Fargo | Market Perform → Outperform |
| Jul-29-16 | Reiterated | Wedbush | Outperform |
| Jan-19-16 | Initiated | Barclays | Underweight |
| Dec-02-15 | Initiated | Deutsche Bank | Hold |
View All
Novocure Ltd Stock (NVCR) Latest News
NovoCure (NVCR) Is Down 5.7% After Q3 Revenue Growth and Expanded International Coverage — Has the Growth Story Changed? - simplywall.st
HC Wainwright Increases Earnings Estimates for NovoCure - MarketBeat
Chart overlay techniques for tracking NovoCure LimitedQuarterly Trade Summary & Free Safe Entry Trade Signal Reports - newser.com
Is NovoCure Limited stock attractive for hedge fundsGDP Growth & Pattern Based Trade Signal System - newser.com
Is NovoCure Limited stock oversold or undervaluedGap Up & Weekly Momentum Stock Picks - newser.com
NovoCure Limited (NASDAQ:NVCR) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
NovoCure Limited (NASDAQ:NVCR) Q3 2025 Earnings Call Transcript - Insider Monkey
How interest rate cuts could boost NovoCure Limited stockJuly 2025 Opening Moves & Verified Chart Pattern Signals - newser.com
What does recent volatility data suggest for NovoCure LimitedJuly 2025 Reactions & Consistent Profit Trade Alerts - newser.com
NovoCure’s Mixed Q3: Growth Amid Challenges - TipRanks
NovoCure (NVCR): Losses Worsen, Testing Bullish Narrative on Valuation and Growth Potential - simplywall.st
NovoCure (NASDAQ:NVCR) Announces Quarterly Earnings Results - MarketBeat
NovoCure (NASDAQ:NVCR) Price Target Raised to $42.00 - MarketBeat
NovoCure: Q3 Earnings Snapshot - Stamford Advocate
Novocure Ltd earnings beat by $0.09, revenue topped estimates - Investing.com UK
Emerald Mutual Fund Advisers Trust Reduces Position in NovoCure Limited $NVCR - MarketBeat
NovoCure Expands Global Reach Within Nasdaq Today Trends - Kalkine Media
Novocure Ltd. Reports Q3 2025 Financial Results - TipRanks
Order flow analysis tools used on NovoCure Limited2025 Top Decliners & AI Driven Price Predictions - newser.com
Decoding NovoCure Ltd (NVCR): A Strategic SWOT Insight - GuruFocus
HC Wainwright & Co. Raises PT for NVCR, Maintains Buy Rating | N - GuruFocus
Assessing NovoCure (NVCR) Valuation as Investors Revisit Recovery Potential - simplywall.st
NovoCure Ltd (NVCR) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Challenges - Yahoo Finance
Novocure’s Revenue Beats Forecasts As Cancer Pipeline Expands - Finimize
Compared to Estimates, NovoCure (NVCR) Q3 Earnings: A Look at Key Metrics - Yahoo Finance
Novocure (NVCR) Exceeds Q3 Revenue Expectations with Strong Grow - GuruFocus
Emerald Advisers LLC Lowers Stock Position in NovoCure Limited $NVCR - MarketBeat
NovoCure Ltd (NVCR) Q3 Earnings: EPS Loss of $0.33 Beats Estimat - GuruFocus
Novocure (NASDAQ: NVCR) posts $167.2M revenue for the quarter; 4,416 patients on therapy - Stock Titan
Can NovoCure Limited hit a new high this monthJuly 2025 Chart Watch & Safe Entry Point Identification - newser.com
Measuring NovoCure Limited’s beta against major indices2025 Earnings Surprises & Verified High Yield Trade Plans - newser.com
NovoCure (NASDAQ:NVCR) Given New $23.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Real time breakdown of NovoCure Limited stock performanceWeekly Risk Summary & Weekly Setup with High ROI Potential - newser.com
Is NovoCure Limited stock a safe investment in uncertain marketsJuly 2025 Weekly Recap & Advanced Swing Trade Entry Plans - newser.com
Why NovoCure Limited stock remains undervaluedQuarterly Earnings Report & High Accuracy Trade Alerts - newser.com
Will NovoCure Limited stock attract more institutional investorsQuarterly Risk Review & Accurate Entry and Exit Point Alerts - newser.com
Detecting support and resistance levels for NovoCure LimitedJuly 2025 Patterns & Risk Controlled Swing Alerts - newser.com
Is NovoCure Limited (038) stock testing key supportJuly 2025 Sector Moves & Real-Time Market Sentiment Alerts - newser.com
NovoCure’s Phase 3 Glioblastoma Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Will NovoCure Limited (038) stock profit from automation waveMarket Movement Recap & Expert Verified Stock Movement Alerts - fcp.pa.gov.br
JP Morgan Maintains NovoCure (NVCR) Neutral Recommendation - Nasdaq
NovoCure’s LUNAR-2 Study: A New Horizon in Lung Cancer Treatment - TipRanks
Will NovoCure Limited stock outperform growth indexes2025 Top Decliners & Low Risk Entry Point Guides - fcp.pa.gov.br
NovoCure’s TIGER Meso Study: A Promising Update for Pleural Mesothelioma Treatment - TipRanks
NovoCure’s LUNAR-4 Study: A New Horizon in Lung Cancer Treatment - TipRanks
How strong is NovoCure Limited stock revenue growthTrade Exit Summary & Entry Point Strategy Guides - fcp.pa.gov.br
NovoCure’s TIGER France Study: A Potential Game-Changer for Glioblastoma Treatment - TipRanks
JP Morgan Maintains Neutral Rating on NVCR, Lowers Price Target - GuruFocus
What sentiment indicators say about NovoCure Limited stock2025 Price Momentum & Reliable Trade Execution Plans - newser.com
How NovoCure Limited (038) stock responds to job market shiftsJuly 2025 Fed Impact & Safe Swing Trade Setup Alerts - newser.com
Forecasting NovoCure Limited price range with options dataWall Street Watch & Free Community Supported Trade Ideas - newser.com
Novocure Ltd Stock (NVCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novocure Ltd Stock (NVCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Brackmann Christoph | Chief Financial Officer |
Jul 29 '25 |
Buy |
11.59 |
20,000 |
231,800 |
141,150 |
| Stafford Kristin | Director |
Jun 03 '25 |
Sale |
17.28 |
999 |
17,259 |
3,054 |
| LEUNG GABRIEL | Director |
Jun 03 '25 |
Sale |
17.31 |
999 |
17,297 |
81,229 |
| Madden Martin J. | Director |
Jun 03 '25 |
Sale |
17.19 |
999 |
17,176 |
18,674 |
| Scannell Timothy J | Director |
Jun 03 '25 |
Sale |
17.32 |
999 |
17,299 |
6,018 |
| HILLEMAN JERYL L | Director |
Jun 03 '25 |
Sale |
17.26 |
999 |
17,247 |
5,591 |
| Ocean Allyson J | Director |
Jun 03 '25 |
Sale |
17.29 |
999 |
17,269 |
3,054 |
| VERNON W ANTHONY | Director |
Jun 03 '25 |
Sale |
17.35 |
999 |
17,329 |
167,887 |
| Hung David | Director |
Jun 03 '25 |
Sale |
17.30 |
999 |
17,280 |
12,195 |
| Leonard Frank X | EVP, Pres., Novocure Oncology |
Jun 02 '25 |
Sale |
17.50 |
30,196 |
528,413 |
168,452 |
2.29%
1.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):